Sigmond Jennifer, Backus Harold H J, Wouters Dorine, Temmink Olaf H, Jansen Gerrit, Peters Godefridus J
Department of Medical Oncology, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands.
Biochem Pharmacol. 2003 Aug 1;66(3):431-8. doi: 10.1016/s0006-2952(03)00287-9.
Pemetrexed (ALIMTA, MTA) is a novel thymidylate synthase (TS) inhibitor and has shown activity against colon cancer, mesothelioma and nonsmall-cell lung cancer. We induced resistance to Pemetrexed in the human colon cancer cell line WiDr by using a continuous exposure to stepwise increasing Pemetrexed concentrations (up to 20 microM) as well as a more clinically relevant schedule with intermittent exposure (up to 50 microM) for 4 hr every 7 days, resulting in WiDr variants WiDr-cPEM and WiDr-4PEM, respectively. However, using the same conditions, it was not possible to induce resistance in the WiDr/F cell line, a variant adapted to growth under low folate conditions. Mechanisms of resistance to Pemetrexed were determined at the level of TS, folylpolyglutamate synthetase (FPGS) and reduced folate carrier (RFC). WiDr-4PEM and WiDr-cPEM showed cross-resistance to the polyglutamatable TS inhibitor Raltitrexed (6- and 19-fold, respectively) and the nonpolyglutamatable TS-inhibitor Thymitaq (6- and 42-fold, respectively) but not to 5-fluorouracil. The ratios of TS mRNA:beta actin mRNA in WiDr-4PEM and WiDr-cPEM were 5-fold (P=0.01) and 18-fold (P=0.04) higher, respectively, compared to WiDr (ratio: 0.012). In addition, TS protein expression in the resistant WiDr variants was elevated 3-fold compared to WiDr, while the catalytic activity of TS with 1 microM dUMP increased from 30 pmol/hr/10(6) cells in WiDr cells to 2201 and 7663 pmol/hr/10(6) cells in WiDr-4PEM and WiDr-cPEM, respectively. The activity of FPGS was moderately decreased, but not significantly different in all WiDr variants. Finally, no evidence was found that decreased catalytic activity of RFC was responsible for the obtained Pemetrexed resistance. Altogether, these results indicate that resistance to Pemetrexed in the colon cancer cell line WiDr was solely due to upregulation of TS of which all related parameters (mRNA and protein expression and TS activity) were increased, rather than alterations in FPGS or RFC activity.
培美曲塞(力比泰,MTA)是一种新型胸苷酸合成酶(TS)抑制剂,已显示出对结肠癌、间皮瘤和非小细胞肺癌的活性。我们通过连续暴露于逐步增加的培美曲塞浓度(高达20微摩尔)以及更具临床相关性的间歇暴露方案(高达50微摩尔),每7天暴露4小时,在人结肠癌细胞系WiDr中诱导对培美曲塞的耐药性,分别产生了WiDr变体WiDr-cPEM和WiDr-4PEM。然而,在相同条件下,无法在适应低叶酸条件下生长的WiDr/F细胞系中诱导耐药性。在TS、叶酰聚谷氨酸合成酶(FPGS)和还原型叶酸载体(RFC)水平上确定了对培美曲塞的耐药机制。WiDr-4PEM和WiDr-cPEM对可聚谷氨酸化的TS抑制剂雷替曲塞(分别为6倍和19倍)和不可聚谷氨酸化的TS抑制剂Thymitaq(分别为6倍和42倍)表现出交叉耐药性,但对5-氟尿嘧啶没有交叉耐药性。与WiDr(比值:0.012)相比,WiDr-4PEM和WiDr-cPEM中TS mRNA与β-肌动蛋白mRNA的比值分别高5倍(P=0.01)和18倍(P=0.04)。此外,与WiDr相比,耐药的WiDr变体中TS蛋白表达升高了3倍,而在1微摩尔dUMP存在下TS的催化活性从WiDr细胞中的30皮摩尔/小时/10^6细胞分别增加到WiDr-4PEM和WiDr-cPEM中的2201和7663皮摩尔/小时/10^6细胞。FPGS的活性适度降低,但在所有WiDr变体中无显著差异。最后,没有证据表明RFC催化活性降低是导致获得性培美曲塞耐药的原因。总之,这些结果表明,结肠癌细胞系WiDr对培美曲塞的耐药性完全是由于TS上调,其所有相关参数(mRNA和蛋白表达以及TS活性)均增加,而不是FPGS或RFC活性的改变。